Lonza Group Ag · SIX:LONN
Lonza — Merger or Acquisition (March 2024)
9 slides from Lonza's merger presentation, Mar 20, 2024
Slide 1: Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche
Enabling a Healthier World LONZGa Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche Albert M. Baehny, Chairman and CEO ad interim Philippe Deecke, CFO Jean-Christophe Hyvert, President, Biologics 20 March 2024
Slide 2: Transaction Summary
Transaction Summary — Lonza has signed an agreement to acquire the Genentech manufacturing facility for large-scale biologics in Vacaville (US) from Roche — Vacaville (US) site is one of the largest biologics manufacturing facilities in the world by volume, with commercial capacity readily available
Slide 3: One of the World's Largest Biologics Manufacturing Facilities by Volume
One of the World's Largest Biologics Manufacturing Facilities by Volume — Genentech site, acquired by Roche in 2009 — Operational since 2000 and maintained to high standards — Located in Vacaville, California (US) — A total of ~330,000L of large-scale manufacturing capacity for mammalian drug substa
Slide 4: Acquisition Provides Lonza with Readily Available Commercial Capacity
Acquisition Provides Lonza with Readily Available Commercial Capacity — Secures Lonza’s position as one of the world’s leading providers of high-quality manufacturing services for large-scale mammalian drug substance — Expands Lonza’s presence in the US with a West Coast hub to complement existing E
Slide 5: Market Dynamics and Growing Demand Support Additional Large-Scale CDMO Capacity
Market Dynamics and Growing Demand Support Additional Large-Scale CDMO Capacity Mammalian Industry Capacity Utilization Expected Market Share of Installed Mammalian (% Demand / Supply)! Capacity CDMO vs. Pharma! 2013 - 2028 e CDMO Capacity Share 5 = 0, : “ 52% s aE Qc gz 8 78% 71% 5 61% 8 48% € Phar
Slide 6: Details of the Acquisition
Details of the Acquisition — The site will immediately strengthen Lonza’s capacity and capabilities in attractive commercial phase — Additional CAPEX of approximately CHF 500m to upgrade the facility and enhance capabilities at the Investment Vacaville (US) site — Mid-Term Guidance 2024 — 2028 CAPEX
Slide 7: Mid-Term Guidance 2024 - 2028: Sales Growth Updated
Mid-Term Guidance 2024 - 2028: Sales Growth Updated Updated 12 - 15% 32-34% Sales CAGR in CER CORE EBITDA margin (2024 - 2028) in 2028 Previously 11- 13% Double-digit 1.5 -2.0x ROIC Net Debt / CORE EBITDA in 2028 Commitment to investment grade rating of BBB+ Investor Update | March 2024 | 7
Slide 8: Q&A
Q&A
Slide 9: Additional Information and Disclaimer
Additional Information and Disclaimer Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing req